Janux Therapeutics is a biotechnology business based in the US. Janux Therapeutics shares (JANX) are listed on the NASDAQ and all prices are listed in US Dollars. Janux Therapeutics employs 60 staff and has a trailing 12-month revenue of around $8.6 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $11.53 |
|---|---|
| 52-week range | $9.39 - $23.64 |
| 50-day moving average | $17.80 |
| 200-day moving average | $14.64 |
| Wall St. target price | $29.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.33 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.53 from 2023-03-21
| 1 week (2023-03-14) | -19.71% |
|---|---|
| 1 month (2023-02-22) | -32.53% |
| 3 months (2022-12-22) | -4.24% |
| 6 months (2022-09-22) | -13.44% |
| 1 year (2022-03-22) | -26.04% |
|---|---|
| 2 years (2021-03-18) | N/A |
| 3 years (2020-03-18) | N/A |
| 5 years (2018-03-18) | N/A |
| Revenue TTM | $8.6 million |
|---|---|
| Gross profit TTM | $-44,829,000 |
| Return on assets TTM | -11.27% |
| Return on equity TTM | -18.36% |
| Profit margin | 0% |
| Book value | $7.71 |
| Market capitalisation | $553.9 million |
TTM: trailing 12 months
We're not expecting Janux Therapeutics to pay a dividend over the next 12 months.
Janux Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California. .
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.